Skip to main content
< Back to news
Dr. Ana Angulo and Dr. Pablo Engel (Photo: Fundació Bosch i Gimpera Foundation).
 14.11.2023

The University of Barcelona licenses an innovative technology to IMIDomics

The University of Barcelona (UB) has licensed an innovative technology to IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs). The startup is one of the 11 companies chosen to take part in the BCN Health Booster acceleration programme, promoted by the Barcelona Science Park and the Barcelona City Council, in collaboration with Barcelona Activa and support from Biocat. 

IMIDomics will benefit from the UB’s technology and expertise in areas such as the discovery of new molecules in various research projects aimed at developing innovative therapeutic approaches. The licensing agreement includes sole intellectual property rights over the technology, as well as specific patents and proprietary know-how related to it. This technological breakthrough results from research carried out over the last few years by researchers from the Faculty of Medicine and Health Sciences, Dr. Ana Angulo and Dr. Pablo Engel, leader of the project.

“With this partnership we aim to discover valuable ideas and solutions that can make a significant difference to patients’ lives. All of us at the UB are delighted to collaborate with IMIDomics to advance the frontiers of research on IMIDs”, says Prof. Engel.

H. Daniel Pérez,  chief developmentofficer at IMIDomics, also expresses his “enthusiasm” for this collaboration which marks “a significant milestone for IMIDomics as we continue our relentless research into new therapies for IMIDs. We believe that working closely with the UB will help us expedite our research and ultimately benefit patients suffering from IMIDs”.

Developing new therapeutic targets

IMIDomics is a company that focuses on identifying therapeutic targets for autoimmune diseases using the company’s proprietary Clinical Discovery Engine™, a multi-dimensional, integrated, data-driven platform for discovering the underlying mechanisms of IMIDs. This license and collaboration with the UB will further the company’s ongoing scientific discoveries and the development of IMIDomics’ drug targets IMB-1003 and IMB-1004 for the treatment of autoimmune diseases.

Severe diseases with no cure

IMIDs are a group of severe diseases that affect millions of people worldwide and currently have no successful treatment. Despite differences between them —for they include a wide variety of pathologies such as inflammatory bowel disease, atopic dermatitis, allergies, and others — they share similar genetic, clinical, and environmental factors as well as similar inflammatory mechanisms. Moreover, these are all debilitating and painful conditions that currently have no cure and, in many cases, no successful treatment for the symptoms either.

» Link to the news: Bosch i Gimpera Foundation [+]